Fexofenadine Hydrochloride Tablets, 180 mg recall — Sun Pharmaceutical Industries Inc (Class III)

Sun Pharmaceutical Industries Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Fexofenadine Hydrochloride Tablets, 180 mg — a Class III recall, initiated 2026-06-01 and posted to the FDA enforcement report on 2026-07-08, under recall number D-0654-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications”. From the product description, the form is tablets, the strength given is 180 mg and the package is described as 150 Tablets. 1 National Drug Code number is printed in the record: 66336-561-30. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99110. Sun Pharmaceutical Industries Inc accounts for 6 recall records in the indexed dataset. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0654-2026
FDA event ID 99110
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Sun Pharmaceutical Industries Inc
Recall initiated 2026-06-01
Reported by FDA 2026-07-08
Report lag 37 days from initiation to report
Distribution U.S. Nationwide — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distributed by: Ohm Laboratories, Inc., New Brunswick, NJ 08901. NDC 66336-561-30

Reason reported by FDA

Failed Impurities/Degradation Specifications

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 22-word product description above; each is a literal substring of it.

Product named Fexofenadine Hydrochloride Tablets
Form Tablets
Strength 180 mg
Package 150 Tablets
NDC 66336-561-30
Distributed by Ohm Laboratories, Inc.

Other indexed recalls from Sun Pharmaceutical Industries Inc

6 indexed records name Sun Pharmaceutical Industries Inc as the recalling firm, across 5 FDA events, reported 2026-06-10 to 2026-07-08. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Perampanel CIII Tablets, 6mgD-0628-2026Class II6mg · Tablets2026-07-01
DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mLD-0580-2026Class I50 mg/25 mL · Injection2026-06-17
Budesonide Inhalation Suspension, 1mg/2mLD-0607-2026Class II1mg/2mL · Suspension2026-06-17
Xyvona (levorphanol tartrate tablets), 2mgD-0598-2026Class II2mg · Tablets2026-06-10
Xyvona (levorphanol tartrate tablets), 3mgD-0599-2026Class II3mg · Tablets2026-06-10

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 4 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.Class III2026-07-01
Lidolog Kit, 2%D-0713-2026Asclemed Usa Inc.Class III2026-07-29
Dabigatran etexilate Capsules, 110 mgD-0735-2026Ascend Laboratories, LLCClass III2026-07-29
Dabigatran etexilate Capsules, 150 mgD-0736-2026Ascend Laboratories, LLCClass III2026-07-29

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 7 nearest to 2026-07-08 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz Inc5 mg · Extended-Release Capsules2026-06-24
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLC1mg/mL · Injection2026-06-17
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLC50 mg · Tablets2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLC2% · Injection2026-06-10
Dabigatran Etexilate Capsules, 150 mgD-0737-2026Ascend Laboratories, LLC150 mg · Capsules2026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0738-2026Ascend Laboratories, LLC75 mg · Capsules2026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0739-2026Ascend Laboratories, LLC75 mg · Capsules2026-08-05

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 66336-561-30 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Sun Pharmaceutical Industries Inc (6 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0654-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0654-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-08
Ingested
2026-08-22
Record hash
0d34895c050bde9f

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.